Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). [electronic resource]
Producer: 20121219Description: 3588-95 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Biopsy, Needle
- Colorectal Neoplasms -- drug therapy
- Confidence Intervals
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Female
- Fluorouracil -- therapeutic use
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Leucovorin -- therapeutic use
- Male
- Middle Aged
- Neoplasm Invasiveness -- pathology
- Neoplasm Staging
- Organoplatinum Compounds -- therapeutic use
- Patient Selection
- Proportional Hazards Models
- Quinazolines -- therapeutic use
- Risk Assessment
- Survival Analysis
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.